# ClinicalTrials.gov record NCT02640118

> PeptideScanner retained ClinicalTrials.gov record NCT02640118 at 2026-07-30T20:27:50.520Z. Its registry update date was 2020-05-07, and PeptideScanner's reviewed identity mapping was lixisenatide.

- Evidence object: `story:clinicaltrials-gov-nct02640118-lixisenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-05-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02640118-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02640118-lixisenatide-v1.json
- Content SHA-256: `c81ef4af0a7aaf369d51f178d6049e45d256c318938cc31e6c4d037c913918f1`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02640118 ([`ctg-observation-nct02640118-2020-05-07-2324e26bccb0`](#source-ctg-observation-nct02640118-2020-05-07-2324e26bccb0))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02640118 at 2026-07-30T20:27:50.520Z. Its registry update date was 2020-05-07, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02640118-2020-05-07-2324e26bccb0`](#source-ctg-observation-nct02640118-2020-05-07-2324e26bccb0))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02640118 at 2026-07-30T20:27:50.520Z. Its registry update date was 2020-05-07, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02640118-2020-05-07-2324e26bccb0`](#source-ctg-observation-nct02640118-2020-05-07-2324e26bccb0))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02640118-2020-05-07-2324e26bccb0`](#source-ctg-observation-nct02640118-2020-05-07-2324e26bccb0))

## Sources

<a id="source-ctg-observation-nct02640118-2020-05-07-2324e26bccb0"></a>
- **ClinicalTrials.gov record NCT02640118 · retained source version 2020-05-07:2324e26bccb0b4d60bf9527e0d62f4377a8ad13ad89723f82a4939a0aa52a7a4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02640118) (`ctg-observation-nct02640118-2020-05-07-2324e26bccb0`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02640118." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02640118-lixisenatide-v1.json SHA-256: c81ef4af0a7aaf369d51f178d6049e45d256c318938cc31e6c4d037c913918f1.